BioDech: A Global Life Sciences Broadcast Series

Latest Episode | Previous Episodes

In today's competitive landscape, life sciences companies routinely face a myriad of legal complexities and regulatory issues, from early-stage financing for clinical trials and IPO preparedness, to antitrust, securities or patent disputes post-product launch. Despite the challenges, innovation in the market is more active than ever.

To help companies navigate these issues, BioDech brings together life sciences industry leaders with lawyers from Dechert’s cross-practice global life sciences team to discuss the challenges and opportunities that may arise at every phase of the life sciences life cycle, from discovery through development, clinical testing, promotion and sales.

Latest Episode: Episode 6 – One in Four: What Makes Life Sciences Companies So Vulnerable to Securities Class Actions

September 14, 2023 – Joni Jacobsen, co-chair of the global securities and complex litigation team and Angela Liu, securities litigation partner are joined by Tiffany Engsell, Senior Counsel, Litigation & Government Investigations, Bristol Myers Squibb, to discuss securities fraud class actions against U.S. life sciences companies and what to look out for after your company becomes public.

Speakers:
Joni Jacobsen | Partner & Co-Chair, Global Securities and Complex Litigation, Dechert
Angela Liu | Partner, Securities Litigation, Dechert
Tiffany Engsell | Senior Counsel, Litigation & Government Investigations, Bristol Myers Squibb

About Dechert's Life Sciences Practice

Dechert’s life sciences group delivers industry expertise and commercial judgment to help leading life sciences companies navigate their most complex and demanding transactional, intellectual property and litigation matters. Our global multi-disciplinary team has the reach, resources and experience to provide comprehensive transactional, regulatory and dispute resolution services anywhere in the world. Learn more.

Previous BioDech Episodes:

Episode 5 - Executive Compensation Considerations for a Successful IPO

May 15, 2023 – Executive compensation plays a critical role in preparing for a successful IPO. In the fifth episode of BioDech, we discuss understanding the market, identifying your organization’s peer groups, designing competitive compensation components, and other regulatory and disclosure requirements. Speakers include Dechert's Kevin Kay, and Alvarez & Marsal's John Schultz and Brennan Rittenhouse.

Episode 4 - What Every Life Sciences Company Needs to Know About Cybersecurity

April 18, 2023 – In the fourth episode of BioDech, our global life sciences broadcast series, we discuss major developments on the threat landscape, proactive responses to potential threats, and how to ensure your cybersecurity preparations can withstand the scrutiny of due diligence. Speakers include Dechert's Brenda Sharton and Sophie Pelé, Stroz Friedberg's John Ansbach and Moderna's Zoe Philippides.

Episode 3 - Corporate Governance Considerations Pre-IPO

March 21, 2023 – In the third episode of BioDech, we discuss corporate governance considerations leading up to an IPO, including board composition, financial controls and overall risk management, and forward-looking concerns for newly public companies. Speakers include C4 Therapeutics' Jolie Siegel, Aquestive Therapeutics' Marco Taglietti, and Dechert's Stephen Leitzell and John Alessi.

Episode 2 - Choosing an Investment Bank

February 22, 2023 – In our second episode of BioDech, we discuss the process of selecting an investment bank for an IPO. Speakers include Danforth Advisors' Gregg Beloff, SVB Securities' Gabriel Cavazos, Verona Pharma's Mark Hahn and Dechert's David Rosenthal.

Episode 1 - When Do You Know You’re Ready to Go Public?

January 18, 2023 – In the inaugural episode of our BioDech broadcast series, we discuss how biotech companies can determine whether they are ready to go public. Speakers include J.P. Morgan Investment Banking Global Chairman Philip Ross and Dechert's Anna Tomczyk and Greg Schernecke.